Dasari A. Shen D. Halperin B. et al.

Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states.

JAMA Oncol. 3: 1335-1342Frilling A. Modlin I.M. Kidd M. et al.

Recommendations for management of patients with neuroendocrine liver metastases.

Lancet Oncol. 15: e8-e21Pavel M. Baudin E. Couvelard A. et al.

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Neuroendocrinology. 95: 157-176Bilimoria K.Y. Bentrem D.J. Wayne J.D. et al.

Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.

Ann Surg. 249: 63-71Keck K.J. Maxwell J.E. Utria A.F. et al.

The distal predilection of small bowel neuroendocrine tumors.

Ann Surg Oncol. 25: 3207-3213Kuiper D.H. Gracie Jr., W.A. Pollard H.M.

Twenty years of gastrointestinal carcinoids.

Cancer. 25: 1424-1430Howe J.R. Cardona K. Fraker D.L. et al.

The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society.

Pancreas. 46: 715-731Niederle B. Pape U.F. Costa F. et al.

ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum.

Neuroendocrinology. 103: 125-138Tierney J.F. Chivukula S.V. Wang X. et al.

Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.

Surgery. 165: 644-651Mayo S.C. de Jong M.C. Pulitatno C. et al.

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.

Ann Surg Oncol. 17: 3129-3136Givi B. Pommier S.J. Thompson A.K. et al.

Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.

Surgery. 140 (): 891-897Sarmiento J.M. Heywood G. Rubin J. et al.

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

J Am Coll Surg. 197: 29-37Chambers A.J. Pasieka J.L. Dixon E. et al.

The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Surgery. 144 (): 645-651Bennett S. Coburn N. Law C. et al.

Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis.

Ann Surg. ()Gangi A. Manguso N. Gong J. et al.

Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection.

Ann Surg Oncol. 27: 4525-4532Ahmed A. Turner G. King B. et al.

Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

Endocr Relat Cancer. 16: 885-894Wang S.C. Parekh J.R. Zuraek M.B. et al.

Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

Arch Surg. 145: 276-280Kasai Y. Mahuron K. Hirose K. et al.

A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.

J Surg Oncol. 122: 204-211Ohrvall U. Eriksson B. Juhlin C. et al.

Method for dissection of mesenteric metastases in mid-gut carcinoid tumors.

World J Surg. 24: 1402-1408Tran C.G. Sherman S.K. Howe J.R.

Small bowel neuroendocrine tumors.

Curr Probl Surg. 57: 100823Landry C.S. Lin H.Y. Phan A. et al.

Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.

World J Surg. 37: 1695-1700Daskalakis K. Karakatsanis A. Hessman O. et al.

Association of a prophylactic surgical approach to stage iv small intestinal neuroendocrine tumors with survival.

JAMA Oncol. 4: 183-189Hallet J. Law C. Commonwealth S.

Neuroendocrine tumours research collaborative surgical, role of primary tumor resection for metastatic small bowel neuroendocrine tumors.

World J Surg. 45: 213-218Poultsides G.A. Huang L.C. Chen Y. et al.

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Ann Surg Oncol. 19: 2295-2303Dong D.H. Zhang X.F. Poultisides G. et al.

Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors </=2 cm after curative resection: A multi-institutional study of 392 cases.

J Surg Oncol. 120: 1071-1079Cherenfant J. Stocker S.J. Gage M.K. et al.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Surgery. 154 (): 785-791Sadot E. Reidy-Lagunes L. Tang L.H. et al.

Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study.

Ann Surg Oncol. 23: 1361-1370Gaujoux S. Partelli S. Maire F. et al.

Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.

J Clin Endocrinol Metab. 98: 4784-4789Lee L.C. Grant C.S. Salomao D.R. et al.

Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.

Surgery. 152: 965-974Kurita Y. Hara K. Kuwahara T. et al.

Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.

J Gastroenterol. 55: 543-552Barenboim A. Lahat G. Nachmany I. et al.

Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors.

J Gastrointest Surg. 24: 1366-1374Rosenberg A.M. Friedmann P. Del Rivero J. et al.

Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors.

Surgery. 159: 302-309Regenet N. Carrere N. Boulanger G. et al.

Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study.

Surgery. 159: 901-907Zaidi M.Y. Lopez-Aguiar A.G. Switchenko J.M. et al.

A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients.

Ann Surg. 270: 422-433Howe J.R. Merchant N.B. Conrad C. et al.

The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors.

Pancreas. 49: 1-33Falconi M. Erikkson B. Kaltsas G. et al.

ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.

Neuroendocrinology. 103: 153-171Falconi M. Bartsch D.K. Erikkson B. et al.

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Neuroendocrinology. 95: 120-134Mansour J.C. Chavin K. Morris-Stiff G. et al.

Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.

HPB (Oxford). 21: 515-523

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 202X. NCCN.org. Accessed April 1, 2022.

Tanaka M. Heckler M. Mihaljevic A.L. et al.

Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors.

Ann Surg Oncol. 28: 1614-1624Mao R. Zhao H. Li K. et al.

Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the National Cancer Database.

Ann Surg Oncol. 26: 2722-2729Conrad C. Kutlu O.C. Dasari A. et al.

Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas.

J Gastrointest Surg. 20: 1966-1974Lopez-Aguiar A.G. Ethun C.G. Zaidi M.Y. et al.

The conundrum of < 2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management.

Surgery. 166: 15-21Mehrabi A. Fischer L. Hafezi M. et al.

A systematic review of localization, surgical treatment options, and outcome of insulinoma.

Pancreas. 43: 675-686Partelli S. Cirocchi R. Crippa S. et al.

Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.

Br J Surg. 104: 34-41Sadowski S.M. Pieterman C.R.C. Perrier N.D. et al.

Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Endocr Relat Cancer. 27: R145-R161de Rooij T. van Hilst J. van Santvoort H. et al.

Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial.

Ann Surg. 269: 2-9van Hilst J. de Rooij T. Bosscha K. et al.

Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.

Lancet Gastroenterol Hepatol. 4: 199-207Boone B.A. Zenati M. Hogg M.E. et al.

Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve.

JAMA Surg. 150: 416-422Ricci C. Casadei R. Taffurelli G. et al.

Minimally Invasive Pancreaticoduodenectomy: What is the Best “Choice”? A Systematic Review and Network Meta-analysis of Non-randomized Comparative Studies.

World J Surg. 42: 788-805Huttner F.J. Koessler-Ebbs J. Hackert T. et al.

Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms.

Br J Surg. 102: 1026-1036Dragomir M.P. Sabo A.A. Petrescu G.E.D. et al.

Central pancreatectomy: a comprehensive, up-to-date meta-analysis.

Langenbecks Arch Surg. 404: 945-958Dalla Valle R. Cremaschi E. Lamecchi L. et al.

Open and minimally invasive pancreatic neoplasms enucleation: a systematic review.

Surg Endosc. 33: 3192-3199Wakabayashi T. Felli E. Cherkaoui Z. et al.

Robotic Central Pancreatectomy for Well-Differentiated Neuroendocrine Tumor: Parenchymal-Sparing Procedure.

Ann Surg Oncol. 26: 2121Keutgen X.M. Nilubol N. Glanville J. et al.

Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.

Surgery. 159: 311-318Dasari A. Mehta K. Byers L.A. et al.

Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.

Cancer. 124: 807-815Patel S.P. Othus M. Chae Y.K. et al.

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

Clin Cancer Res. 26: 2290-2296Bagante F. Spolverato G. Merath K. et al.

Neuroendocrine liver metastasis: The chance to be cured after liver surgery.

J Surg Oncol. 115: 687-695Graff-Baker A.N. Sauer D.A. Pommier S.J. et al.

Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients.

Surgery. 156 (): 1369-1376Panzuto F. Boninsegna L. Fazio N. et al.

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

J Clin Oncol. 29: 2372-2377Scott A.T. Breheny P.J. Keck K.J. et al.

Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).

Surgery. 165: 166-175

The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Ann Surg Oncol. 27: 3270-3280Morgan R.E. Pommier S.J. Pommier R.F.

Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.

Surgery. 163: 218-225Chen J.X. Wileyto E.P. Soulen M.C.

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.

Trials. 19: 390Mayo S.C. de Jong M.C. Bloomston M. et al.

Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.

Ann Surg Oncol. 18: 3657-3665Yao J.C. Fazio N. Singh S. et al.

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

J Clin Oncol. 34: 3906-3913Caplin M.E. Pavel M. Cwikla A. et al.

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

N Engl J Med. 371: 224-233Strosberg J. El-Haddad G. Wolin E. et al.

Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.

N Engl J Med. 376: 125-135Rinke A. Wittenberg M. Schade-Brittinger C. et al.

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

Neuroendocrinology. 104: 26-32Kaderli R.M. Spanjol M. Kollar A. et al.

Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis.

JAMA Oncol. 5: 480-489Rinke A. Muller H.H. Schade-Brittinger C. et al.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

J Clin Oncol. 27: 4656-4663Yao J.C. Fazio N. Singh S. et al.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Lancet. 387: 968-977Raymond E. Dahan L. Raoul J.L. et al.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

N Engl J Med. 364: 501-513Kunz P.L. Catalano P.J. Nimeiri H. et al.

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

J Clin Oncol. 36: 4004